ARBOK-TELORISE (Telomerase Platform)

Overview

ARBOK-TELORISE extracts native human telomerase from immortalized cancer cell cultures — principally HeLa — using vacuum-assisted gravitational fractionation. The platform is a repurposed seawater desalination architecture: instead of separating salt from water, it separates a protein-RNA complex from cellular debris by density under vacuum. There are no genetic vectors, no viral transduction, no bacterial synthesis, no chromatography and no centrifugation — only heat, vacuum and density stratification. Because the enzyme is produced by human cells and never chemically processed, it retains authentic folding, carries no exogenous tags and is fully biologically functional.

The economics are the point. Production cost is $200–500 per gram against a market price of $100,000–300,000 per gram as a non-GMP reagent — gross margin above 99 %. Per milligram, that is $0.2–0.5 against $100–200 for bacterial expression and $500–1,000 for CHO/HEK cells.

Applications

Cellular immunotherapy (CAR-T, TCR-T, TIL). T-cells die after 20–30 divisions without telomerase, which is why the therapy fails. Current cost of pure telomerase is $50,000–150,000 per mg; one patient needs 2–20 mg; more than 500,000 patients per year globally are expected on CAR-T. Potential market $5–30 billion per year.

Stem cell rejuvenation. Leading longevity and stem-cell rejuvenation companies require native human telomerase without artificial tags — not murine, not synthetic.

iPSC production. Japan, Korea and the USA grow organs and tissues. Without telomerase cells age out after 40–50 divisions; with it, indefinitely.

Veterinary, luxury segment. Anti-aging therapy for elite horses and dogs, where regulation is minimal and price is not the constraint.

Cosmeceuticals. Creams and serums containing 0.001 % telomerase sell at $1,000+ per 30 ml; a brand needs 0.5–1 g per year for the marketing claim.

Research reagents. Labs, CROs and biotech startups — saleable immediately as a reagent rather than a drug.

Operating Principle

Cancer cells are cultured in a warm zone held at standard human cell-culture temperature, where they divide and express telomerase at maximum rate. Telomerase is a heavy protein-RNA complex, and by molecular weight and density it sediments under gravity into a cooler collection zone below. The whole process runs under deep vacuum, calibrated so that proteins neither denature nor oxidise — the complex survives intact. Lighter cellular debris, membranes and DNA fragments float upward and are drained off separately. Over a multi-day processing cycle a pure telomerase layer accumulates at the bottom of the reactor and is collected directly.

No chromatography, no viral vectors, no synthetic chemistry — physics, vacuum and gravity. As a byproduct the process also yields pure cancer DNA, proteins and other fractions usable in separate research.

Limitations: requires a licence to work with HeLa, which most laboratories already hold; alternatively iHeLa (immortalized stem derivatives) can be substituted.

Key Parameters

| Parameter | Value |

|---|---|

| Source cells | HeLa and other immortalized human cancer lines |

| Bioreactor | vertical vacuum phase-fractionation unit |

| Cell zone temperature | standard human cell-culture temperature |

| Vacuum | deep vacuum, calibrated to protect protein structure |

| Batch duration | a multi-day processing cycle |

| Energy consumption | modest, reactor-size dependent |

| Yield | 2–10 mg per litre of culture |

| Recovery efficiency | >85 % |

| Purity | >95 % native TERT complex (SDS-PAGE and activity assay) |

| Storage stability | >6 months at −20 °C |

| Batch-to-batch variability | <10 % |

| Scalability | small pilot units scaling to industrial-scale reactors |

Comparison against conventional production routes:

| Parameter | ARBOK-TELORISE | Bacterial expression | CHO/HEK cells |

|---|---|---|---|

| Telomerase identity | native human | synthetic, non-human | modified |

| Yield per litre | 2–10 mg | 0.1–0.5 mg | 0.5–2 mg |

| Cost per mg | $0.2–0.5 | $100–200 | $500–1,000 |

| Post-processing | none (gravity-purified) | chromatography, tags | centrifugation, FPLC |

| Regulatory classification | reagent (non-GMP) | often therapeutic | clinical |

| Cycle time | a few days | 7–14 days | 10–21 days |

Architecture and Components

Vertical vacuum phase-fractionation reactor with a thermal gradient: warm cell zone held at standard cell-culture temperature above, cooler collection zone below. Vacuum system held under deep vacuum throughout the run. Upper drain for light debris, membranes and DNA fragments. Bottom collection layer for the telomerase concentrate. Quality control: ELISA, qPCR, protein integrity assays, SDS-PAGE, activity assay. Pilot line scaling from small trial units up to industrial-scale reactors.

No chromatography columns, no centrifuges, no FPLC, no reagent handling.

Advantages

Technical: native human enzyme with authentic folding and no exogenous tags, which bacterial and CHO routes cannot deliver; no promoter mutations; grams rather than micrograms per campaign; a processing cycle measured in days against 7–21 days for conventional routes; no chemical processing to degrade activity; recoverable byproducts including pure cancer DNA and proteins.

Economic: $0.2–0.5 per mg against $100–200 for bacterial and $500–1,000 for CHO — 200 to 2,000 times cheaper. Production cost $200–500 per gram against a reagent sale price of $100,000–300,000 per gram.

Regulatory: classified as a non-GMP reagent, so it can be sold immediately without an FDA pathway, while bacterial and mammalian-cell products often fall under therapeutic or clinical classification from the outset.

Capital: full pilot reactor CAPEX below $500,000.

Integrations

Built on the same vertical vacuum phase-separation core as ARBOK's desalination line — the reactor is a repurposed seawater evaporator.

ARBOK MedZWD · ARBOK-PHARMIX · ARBOK-VC (Vacuum Cracking) · 3X

Deployment & Operation

Commercial sequence: begin with reagent sales, which carry no pharmaceutical regulation → monetize the first 10–50 grams at an estimated $10–15 million gross → reinvest in a GMP reactor line and IND submission → enter longevity, regenerative medicine and personalized therapy.

Technical next steps: secure a HeLa licence or shift to iHeLa (immortalized stem derivatives); scale the vertical reactor line from small pilot units to industrial-scale reactors; establish quality control through ELISA, qPCR and protein integrity assays.

Clinical path: prepare an IND for Phase I–II trials in aging-related disease, cardiac regeneration and immune recovery, with first administration to 20–50 patients under consent and supervision.

First-year target: 100 g output, $10–30 million revenue, CAPEX under $500,000.

TRL

TRL 5–6. Validated in a lab-scale prototype covering both cell culture and extraction. Pre-industrial setup under development and ready for pilot funding.

Remaining: GMP-grade facility, manufacturing scale-up from pilot to full industrial culture scale, regulatory approval path if clinical diagnostics are intended, and commercial supply agreements with CROs and labs.

Market Potential

Telomerase is a key biomarker for both aging and cancer — 85–90 % of tumours activate it. The telomere detection market stood at $640 million in 2025, growing 9 % per year toward $1.2 billion by 2032. Capturing 10–20 % of the production-grade reagent market represents $64–240 million by 2032.

The larger prize is cellular immunotherapy. With more than 500,000 CAR-T patients per year globally and 2–20 mg required per patient at a current cost of $50,000–150,000 per mg, that segment alone represents a $5–30 billion annual market — currently constrained precisely by the cost and scarcity of the enzyme.

Adjacent demand: longevity companies requiring untagged native human enzyme; iPSC producers in Japan, Korea and the USA; a low-regulation, high-margin veterinary luxury segment; and cosmeceutical brands needing 0.5–1 g per year each.

Typical Project Economics

| Item | Value |

|---|---|

| Production cost (reactor-based) | $200–500 per gram |

| Sale price (non-GMP reagent) | $100,000–300,000 per gram |

| Gross margin | >99 % |

| CAPEX, full pilot reactor | <$500,000 |

| First-year output target | 100 g |

| First-year revenue target | $10–30 M |

Per milligram: $0.2–0.5 production cost against $50,000–150,000 current market price for pure telomerase in the immunotherapy context.

Risk Factors

A HeLa licence is required, though most laboratories hold one; the alternative is a shift to iHeLa derivatives. Long-term activity stability of the final product and batch reproducibility under GMP conditions remain to be demonstrated. If clinical use is intended, FDA or CE approval carries a 5+ year timeline and $10M+ cost — which is why the commercial path deliberately starts with reagent sales. Competition comes from academic labs producing telomerase on a custom basis at low cost but inconsistent quality, and from established suppliers at high prices. Adoption requires educating laboratories that telomerase has been expensive because of scarcity rather than inherent cost.

Scale-up from a lab prototype to full industrial-scale reactors is unproven, and the yield and purity figures derive from lab-scale work.

Related Technologies

TELORISE (Electro-Thermal Energy Conversion) · ARBOK MedZWD · ARBOK-PHARMIX · ARBOK-VC (Vacuum Cracking) · 3X